DNA Therapy Slashes Bad Cholesterol by 50% Without Statin Side Effects
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
20 articles
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
When the DNA-repair gene EXO1 is overproduced, it damages DNA instead of fixing it—exposing a hidden vulnerability in multiple cancers.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
Scientists discover how small cell lung cancer uses inflammation to become more aggressive and resistant to treatment.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
A new Oxford tool using 5.6 million patient records shows serious statin muscle side effects are rare, yet 60% of eligible patients skip the drug.
Mouse study reveals the FXR bile acid receptor links gut microbes to arterial plaque in sleep apnea, hinting at new preventive targets.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
Researchers identify N4BP2, the enzyme behind chromothripsis - a genetic catastrophe that helps one in four cancers rapidly evolve and resist treatment.
Researchers discovered why fibrolamellar carcinoma resists immunotherapy and found an existing drug can free trapped T cells to fight it.
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
MYC protein doesn't just fuel tumor growth — it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
New research reveals how tumors reprogram neutrophils to produce CCL3, turning immune defenders into cancer allies.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Updated guidelines recommend cholesterol screening in childhood and tracking genetic factors like lipoprotein(a) for personalized prevention.